Company: RVRC
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-013823
Chunk: 46

Company: Revium Rx.
Filing Date: 2025-02-14
Form: S-1
Chunk 46
---
                       |  23,726 |   |
| Total capitalization                                                                                                                                                                                                                                                                                        |     | $                        |  19,323 |   |     |           |  19,326 |   |     |                       |  23,726 |   |

The number of the Common Stock to be issued and outstanding immediately after this offering as shown above assumes that all of the Common Stock offered hereby are sold, and is based on 60,729,100, Common Stock issued and outstanding as of the date of this prospectus. This number excludes:

| ● | 4,960,000 Common Stock issuable upon the exercise of                                                                                 
 options issued to directors, employees and consultants under our incentive option plan outstanding as of such date, with the average 
 exercise prices at $0.31 per share, of which options to purchase 3,790,000 Common Stock were vested as of such date;                 |

| ● | 2,240,000 Common Stock reserved for future issuance 
 under our 2021 Global Share Incentive Plan (2021).  |

| ● | 6,372,265 Common Stock issuable upon the exercise of                                                              
 our outstanding warrants with the average exercise price of $1.16 per share, exercisable until December 31, 2026; |

<div align='center'>27

DILUTION</div>

If you purchase shares underlying the Units offered by the Company in this Primary Offering, you may experience dilution to the extent of the difference between the price per share you pay in this Primary Offering and the net tangible book value per share of our Common Stock immediately after this offering. The net tangible book value of our Common Stock on September 30, 2024 was approximately $5.7 million, or approximately $0.10 per share. Net tangible book value per share is equal to the amount of our total tangible assets, less total liabilities, divided by the aggregate number of shares of our Common Stock outstanding.

Our pro forma net tangible book value as of September 30, 2024 was $5.7 million, or $0.09 per Share. Pro forma net tangible book value per share represents total tangible assets less total liabilities, divided by the number of common Stock outstanding as of September 30, 2024, after giving effect to the exercise of 2,800,000 options into 2,800,000 common stock at an exercise price of $0.001.

After giving effect to the assumed sale by us of